No causative genes and no inheritance pattern are certified for primary sclerosing cholangitis in this packet, so the genetic basis is not described here. The packet lists an OMIM entry (613806) and records autoimmunity as a very frequent feature, but it does not state a cause.

Diagnostic methods are not certified in this packet. The annotated features above include biliary tract abnormalities and elevated alkaline phosphatase of hepatic origin, which the packet lists as features of the condition rather than as diagnostic criteria.

No FDA-approved treatments are certified in this packet, and foundational therapies are not listed, so the packet does not establish a current approved option for this condition. FDA orphan-drug records list many investigational products with DESIGNATED status for this indication. Designation is a development-stage status and is not an approval; a few records carry WITHDRAWN status. Additional care approaches, including supportive and multidisciplinary management, are not certified in this packet and are not described here.

The packet definition describes the disease as slowly progressive, with bile duct inflammation and destruction that lead to cholestasis, fibrosis, cirrhosis and ultimately liver failure. No survival figures or individual-level outlook are certified in this packet, and the course varies between individuals.

ClinicalTrials.gov records in the packet indicate active research. Examples include NCT05627362, a Phase 2 study of elafibranor in adults with PSC sponsored by Ipsen (active, not recruiting, started 2022-12-29); NCT07387549, a Phase 3 study of elafibranor in adults with PSC sponsored by Ipsen (recruiting, started 2026-05-14); and NCT06286709, a Phase 2 study of faecal microbiota transplantation in PSC sponsored by the University of Birmingham (recruiting, started 2024-03-27). Trial listings change over time, and the ClinicalTrials.gov search page provides current records.